Skip to main content

Nanogen Submits Prototype of Rapid Flu Dx to CDC

NEW YORK (GenomeWeb News) - Nanogen has submitted an influenza diagnostic to the US Centers for Disease Control and Prevention for evaluation for further development, the company said today.
Nanogen said this submission fulfills a second-phase milestone requirement on a contract CDC awarded to Nanogen and its business partner, the San Francisco-based HX Diagnostics.
The company said it will continue to develop the point-of-care influenza diagnostic and will undertake clinical trials pending approval and funding from the CDC.
Around 36,000 people in the US die each year from influenza infections, the company said.
The CDC is concerned about the possibility of a deadly influenza subtype arising and causing a pandemic and is funding development of tests that can act as “sentinels” for potential outbreaks, Nanogen said.

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.